Samsung BioLogics pre-markets $2bn listing
Samsung BioLogics Co has started gauging investor interest for an up to W2.25tr ($2bn) IPO on the main Kospi board in South Korea, with bookbuilding set to begin in mid-October.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: